{
    "clinical_study": {
        "@rank": "127823", 
        "arm_group": {
            "arm_group_label": "Pioglitazone 15 to 30 mg", 
            "description": "administered orally once daily before or after breakfast for 3 years."
        }, 
        "brief_summary": {
            "textblock": "This study is designed to determine the onset of new cerebral and cardiovascular events and\n      changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on\n      long-term pioglitazone (Actos Tablets) treatment."
        }, 
        "brief_title": "Pioglitazone Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\"", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of pioglitazone (Actos Tablets) in\n      patients with type 2 diabetes mellitus, designed to determine the onset of new cerebral and\n      cardiovascular events and changes in metabolic syndrome parameters, and to analyze the\n      association between patient baseline characteristics, including any metabolic\n      syndrome-related risk factors, and the onset of new cerebral and cardiovascular events in an\n      exploratory setting.\n\n      Participants will be patients with type 2 diabetes mellitus. The planned sample size is\n      20,000.\n\n      The usual adult dosage is 15 to 30 mg of pioglitazone administered orally once daily before\n      or after breakfast."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have type 2 diabetes mellitus and have undergone measurements for all\n             of the following parameters to be included in this survey:\n\n        Waist circumference, height, body weight, blood pressure, HbA1c, fasting triglyceride,\n        HDL-cholesterol\n\n        Exclusion Criteria:\n\n          -  Patients meeting any of the following criteria (1) to (5) will be excluded:\n\n               1. Patients with any contraindications to pioglitazone (Actos Tablets) treatment as\n                  specified below:\n\n                  Cardiac failure, history of cardiac failure, severe ketosis, diabetic coma or\n                  precoma, type 1 diabetes mellitus, serious hepatic dysfunction, serious renal\n                  dysfunction, severe infection, perioperative state, serious trauma, history of\n                  hypersensitivity to any ingredients of Actos, pregnancy or possible pregnancy\n\n               2. Patients aged < 20 or \u2265 75 years\n\n               3. Patients who currently have or have had any of the following: myocardial\n                  infarction, angina pectoris, cardiomyopathy, hypertensive heart disease\n                  (including left ventricular hypertrophy with cardiac hypofunction*), atrial\n                  fibrillation, atrial flutter, valvular disease, aortic dissection, cerebral\n                  infarction, cerebral hemorrhage (including subarachnoid hemorrhage). (*Reduced\n                  cardiac function is roughly defined as having a brain natriuretic peptide [BNP]\n                  \u2265 40 pg/mL.)\n\n               4. Patients who have taken pioglitazone (Actos Tablets) within 3 months before\n                  enrollment in this survey\n\n               5. Patients who have been enrolled in the Blopress special drug use surveillance\n                  \"hypertension: survey on metabolic equivalents (MetS) (Challenge-MetS)\" at each\n                  medical institution."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Type 2 diabetes mellitus"
            }
        }, 
        "enrollment": {
            "#text": "18197", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002975", 
            "org_study_id": "237-016", 
            "secondary_id": "JapicCTI-132328"
        }, 
        "intervention": {
            "arm_group_label": "Pioglitazone 15 to 30 mg", 
            "description": "Pioglitazone tablets", 
            "intervention_name": "Pioglitazone", 
            "intervention_type": "Drug", 
            "other_name": "ACTOS"
        }, 
        "intervention_browse": {
            "mesh_term": "Pioglitazone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "December 1, 2013", 
        "number_of_groups": "1", 
        "official_title": "Actos Tablets Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Cerebral and cardiovascular events include the following: - Sudden death - Cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage - Acute myocardial infarction, angina pectoris requiring intervention or hospitalization for treatment - Cardiac failure requiring hospitalization for treatment - Atrial fibrillation - Aortic dissection", 
                "measure": "Frequency of new cerebral and cardiovascular events", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Changes in metabolic syndrome parameters [i.e., waist circumference, body weight, blood pressure, Glycosylated Hemoglobin (HbA1c), fasting triglyceride, high-density lipoprotein (HDL) cholesterol]", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002975"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Association between patient baseline characteristics, including any metabolic syndrome-related risk factors, and onset of new cerebral and cardiovascular events", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2007", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}